Department of Nuclear Medicine, Heidelberg University Hospital, INF 400, 69120, Heidelberg, Germany.
Department of Nuclear Medicine, Bern University Hospital (Inselspital), Bern, Switzerland.
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi: 10.1007/s00259-018-3965-8. Epub 2018 Mar 1.
Since the introduction of Ga-PSMA-11 PET/CT for imaging prostate cancer (PC) we have frequently observed mediastinal lymph nodes (LN) showing tracer uptake despite being classified as benign. The aim of this evaluation was to further analyze such LN.
Two patient groups with biphasic Ga-PSMA-11 PET/CT at 1 h and 3 h p.i. were included in this retrospective evaluation. Group A (n = 38) included patients without LN metastases, and group B (n = 43) patients with LN metastases of PC. SUV of mediastinal/paraaortal LN of group A (n = 100) were compared to SUV of LN metastases of group B (n = 91). Additionally, 22 randomly selected mediastinal and paraaortal LN of patients without PC were immunohistochemically (IHC) analyzed for PSMA expression.
In group A, 7/38 patients (18.4%) presented with at least one PSMA-positive mediastinal LN at 1 h p.i. and 3/38 (7.9%) positive LN at 3 h p.i. with a SUVmax of 2.3 ± 0.7 at 1 h p.i. (2.0 ± 0.7 at 3 h p.i.). A total of 11 PSMA-positive mediastinal/paraaortal LN were detected in nine patients considering both imaging timing points. SUVmax of LN-metastases was 12.5 ± 13.2 at 1 h p.i. (15.8 ± 17.0 at 3 h p.i.). SUVmax increased clearly (> 10%) between 1 h and 3 h p.i. in 76.9% of the LN metastases, and decreased significantly in 72.7% of the mediastinal/paraaortal LN. By IHC, PSMA-expression was observed in intranodal vascular endothelia of all investigated LN groups and to differing degrees within germinal centers of 15/22 of them (68.1%). Expression was stronger in mediastinal nodes (p = 0.038) and when follicular hyperplasia was present (p = 0.050).
PSMA-positive mediastinal/paraaortal benign LN were visible in a notable proportion of patients. PSMA-positivity on the histopathological level was associated with the activation state of the LN. However, in contrast to LN metastases of PC, they presented with significantly lower uptake, which, in addition, usually decreased over time.
自从 Ga-PSMA-11 PET/CT 用于前列腺癌 (PC) 的成像以来,我们经常观察到纵隔淋巴结 (LN) 尽管被分类为良性,但仍显示示踪剂摄取。本评估的目的是进一步分析这些 LN。
这项回顾性评估纳入了两组在注射后 1 小时和 3 小时进行 Ga-PSMA-11 PET/CT 的患者。A 组(n=38)包括无 LN 转移的患者,B 组(n=43)包括有 PC 淋巴结转移的患者。比较 A 组(n=100)的纵隔/旁腔 LN 的 SUV 与 B 组(n=91)的 LN 转移的 SUV。此外,对 22 例无 PC 的随机选择的纵隔和旁腔 LN 进行 PSMA 表达的免疫组织化学(IHC)分析。
在 A 组中,7/38 例患者(18.4%)在注射后 1 小时至少有 1 个 PSMA 阳性纵隔 LN,3/38 例(7.9%)在注射后 3 小时有阳性 LN,SUVmax 分别为 2.3±0.7 和 2.0±0.7。考虑到两个成像时间点,9 例患者共检测到 11 个 PSMA 阳性纵隔/旁腔 LN。1 小时时 LN 转移的 SUVmax 为 12.5±13.2,3 小时时为 15.8±17.0。76.9%的 LN 转移在 1 小时和 3 小时之间 SUVmax 明显增加(>10%),72.7%的纵隔/旁腔 LN 显著减少。通过 IHC,所有研究 LN 组的淋巴结内血管内皮均观察到 PSMA 表达,其中 15/22 个的生发中心有不同程度的表达(68.1%)。纵隔淋巴结的表达更强(p=0.038),当滤泡增生存在时(p=0.050)。
在相当一部分患者中,可见 PSMA 阳性的纵隔/旁腔良性 LN。在组织病理学水平上的 PSMA 阳性与 LN 的激活状态有关。然而,与 PC 的 LN 转移不同,它们的摄取明显较低,而且通常随着时间的推移而减少。